Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.71 |
| ▸ | MAPT | P10636 | 8/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.66 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363338 | 1.00 | ALDH1A1 (0.71) | ALDH1A1MAPTKDM4EPTP4A1KMT2A | |
| SCHEMBL4317761 | 0.92 | ALDH1A1 (0.81) | ALDH1A1MAPTKDM4EPTP4A1KMT2A | |
| SCHEMBL2139678 | 0.92 | ALDH1A1 (0.81) | ALDH1A1MAPTKDM4EPTP4A1KMT2A | |
| SCHEMBL2139676 | 0.92 | ALDH1A1 (0.81) | ALDH1A1MAPTKDM4EPTP4A1KMT2A | |
| SCHEMBL21457258 | 0.89 | MAPT (0.56) | ALDH1A1MAPTKDM4EPTP4A1KMT2A | |
| SCHEMBL21457262 | 0.89 | MAPT (0.56) | ALDH1A1MAPTKDM4EPTP4A1KMT2A | |
| SCHEMBL8998890 | 0.88 | ALDH1A1 (0.74) | ALDH1A1MAPTKDM4EPTP4A1KMT2A | |
| SCHEMBL20278911 | 0.88 | ALDH1A1 (0.74) | ALDH1A1MAPTKDM4EPTP4A1KMT2A | |
| SCHEMBL8998886 | 0.88 | ALDH1A1 (0.74) | ALDH1A1MAPTKDM4EPTP4A1KMT2A | |
| SCHEMBL10346450 | 0.87 | ALDH1A1 (0.72) | ALDH1A1MAPTKDM4EPTP4A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3553097-B1 | COPOLYMER AND OPTICAL FILM USING SAME | TOSOH CORP (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-11225540-B2 | Copolymer and optical film using same | TOSOH CORPORATION (JP) | 2022-01-18 | — | — | US | disclosed |
| CN-110248971-B | Copolymer and optical film using the same | 东曹株式会社 | 2021-11-02 | — | — | CN | disclosed |
| CN-113416191-A | Method for synthesizing tricyclic framework 2-pyridone/2-pyridine imine compound | 西安交通大学 | 2021-09-21 | — | — | CN | disclosed |
| US-20200095358-A1 | COPOLYMER AND OPTICAL FILM USING SAME | TOSOH CORPORATION (JP) | 2020-03-26 | — | — | US | disclosed |
| EP-3553097-A1 | COPOLYMER AND OPTICAL FILM USING SAME | Tosoh Corporation (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-9283226-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-15 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| EP-1933832-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| EP-1904451-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2008-04-02 | — | — | EP | disclosed |
| EP-1902032-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007125320-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2006136830-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136823-A1 | HETEROCYCLIC CONTAINING AMINES AS KINASE B INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136821-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136837-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| EP-1706385-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005061463-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | ALDH1A1 4114/4885MAPT 4567/4885KDM4E 2466/4885 |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | ALDH1A1 4114/4885MAPT 4567/4885KDM4E 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.